Marshall Wace
INBX icon

Marshall Wace’s Inhibrx INBX Stock Holding History

Marshall Wace’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.4M Sell
20,888
-8,422
-29% -$625K ﹤0.01% 1966
2025
Q4 		$2.32M Buy
29,310
+2,068
+8% +$141K ﹤0.01% 1507
2025
Q3 		$918K Buy
+27,242
New +$671K ﹤0.01% 1972
2025
Q1 		– Sell
-53,586
Closed -$825K – 2843
2024
Q4 		$825K Sell
53,586
-37,061
-41% -$564K ﹤0.01% 1819
2024
Q3 		$1.42M Sell
90,647
-106,853
-54% -$1.5M ﹤0.01% 1508
2024
Q2 		$2.8M Buy
+197,500
New +$3.09M ﹤0.01% 1220

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Marshall Wace's INBX Position: Q1 2026 in Review

Marshall Wace reduced its Inhibrx (INBX) stake by 29% in Q1 2026, selling an estimated $625K and leaving 20,888 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1966.

Marshall Wace first reported a position in INBX in Q2 2024 and has held it in 6 quarters since. The position peaked at $2.8M in Q2 2024. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Marshall Wace held 20,888 shares of Inhibrx worth $1.4M as of Q1 2026.
  • Marshall Wace sold 8,422 Inhibrx shares in Q1 2026, an estimated $625K.
  • Inhibrx made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1966 holding.
  • Marshall Wace first reported a position in Inhibrx in Q2 2024 and has held it in 6 quarters since.
  • Marshall Wace's Inhibrx position peaked at $2.8M in Q2 2024.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.